华北制药：下属公司获得头孢丙烯《化学原料药上市申请批准通知书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Cefprozil, indicating a significant advancement in its product pipeline [1] Group 1 - The company's wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., is responsible for the approved drug [1] - The total R&D investment for the drug has reached 4.8862 million yuan (approximately 0.48862 million) [1]